[Analysis of Clinical Characteristics and Prognosis of AML Patients with Co-Mutation of CEBPA Gene and GATA2 Gene].

Xue-Wei Yang, Shan-Shan Li, Yan-Hua Su, Jia-Yue Sun, Yu-Juan Gao
{"title":"[Analysis of Clinical Characteristics and Prognosis of AML Patients with Co-Mutation of <i>CEBPA</i> Gene and <i>GATA2</i> Gene].","authors":"Xue-Wei Yang, Shan-Shan Li, Yan-Hua Su, Jia-Yue Sun, Yu-Juan Gao","doi":"10.19746/j.cnki.issn.1009-2137.2024.05.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical characteristics and prognosis of patients with co-mutation of <i>CEBPA</i> gene and <i>GATA2</i> gene, so as to facilitate clinicians to formulate more accurate individualized treatment plans for patients.</p><p><strong>Methods: </strong>A total of 43 acute myeloid leukemia (AML) patients with <i>CEBPA</i> double mutations and <i>CEBPA-bZIP</i> domain mutation admitted to the First Affiliated Hospital of Harbin Medical University from January 2017 to April 2022 were included, and the clinical characteristics and prognosis of patients with <i>GATA2</i> gene mutation among them were compared and analyzed.</p><p><strong>Results: </strong>The median age of patients with <i>GATA2</i> gene mutation was 48.0 years, which was significantly lower than 57.0 years of patients without <i>GATA2</i> gene mutation (<i>P</i> < 0.05). However, there were no significant differences in sex, white blood cell count, hemoglobin concentration, platelet count, immunophenotype, bone marrow and peripheral blood blast cell ratio and complete remission rate between the two groups (<i>P</i> >0.05). The median overall survival and event-free survival time of patients with <i>GATA2</i> gene mutation were not reached, while those of patients without <i>GATA2</i> gene mutation were 14.8 and 8.1 months, respectively (both <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The median age of patients with <i>GATA2</i> gene mutation is lower than that of patients without <i>GATA2</i> gene mutation. <i>GATA2</i> gene mutation further prolongs the survival time of AML patients with <i>CEBPA</i> double mutations and <i>CEBPA-bZIP</i> domain mutation.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"32 5","pages":"1313-1316"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.05.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To analyze the clinical characteristics and prognosis of patients with co-mutation of CEBPA gene and GATA2 gene, so as to facilitate clinicians to formulate more accurate individualized treatment plans for patients.

Methods: A total of 43 acute myeloid leukemia (AML) patients with CEBPA double mutations and CEBPA-bZIP domain mutation admitted to the First Affiliated Hospital of Harbin Medical University from January 2017 to April 2022 were included, and the clinical characteristics and prognosis of patients with GATA2 gene mutation among them were compared and analyzed.

Results: The median age of patients with GATA2 gene mutation was 48.0 years, which was significantly lower than 57.0 years of patients without GATA2 gene mutation (P < 0.05). However, there were no significant differences in sex, white blood cell count, hemoglobin concentration, platelet count, immunophenotype, bone marrow and peripheral blood blast cell ratio and complete remission rate between the two groups (P >0.05). The median overall survival and event-free survival time of patients with GATA2 gene mutation were not reached, while those of patients without GATA2 gene mutation were 14.8 and 8.1 months, respectively (both P < 0.05).

Conclusion: The median age of patients with GATA2 gene mutation is lower than that of patients without GATA2 gene mutation. GATA2 gene mutation further prolongs the survival time of AML patients with CEBPA double mutations and CEBPA-bZIP domain mutation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[CEBPA基因和GATA2基因共同突变的急性髓细胞性白血病患者临床特征和预后分析]。
目的:分析CEBPA基因和GATA2基因联合突变患者的临床特征和预后:分析CEBPA基因和GATA2基因联合突变患者的临床特征及预后,以便临床医生为患者制定更准确的个体化治疗方案:纳入2017年1月至2022年4月哈尔滨医科大学附属第一医院收治的CEBPA双基因突变及CEBPA-bZIP结构域突变的急性髓性白血病(AML)患者共43例,比较分析其中GATA2基因突变患者的临床特征及预后:GATA2基因突变患者的中位年龄为48.0岁,明显低于无GATA2基因突变患者的57.0岁(P<0.05)。然而,两组患者在性别、白细胞计数、血红蛋白浓度、血小板计数、免疫表型、骨髓和外周血造血细胞比率以及完全缓解率方面均无明显差异(P >0.05)。GATA2基因突变患者的中位总生存期和无事件生存期未达标,而无GATA2基因突变患者的中位总生存期和无事件生存期分别为14.8个月和8.1个月(P均<0.05):结论:GATA2 基因突变患者的中位年龄低于无 GATA2 基因突变的患者。GATA2基因突变可进一步延长CEBPA双突变和CEBPA-bZIP结构域突变的急性髓细胞性白血病患者的生存时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中国实验血液学杂志
中国实验血液学杂志 Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
7331
期刊介绍:
期刊最新文献
[Effect and Influencing Factors of Peripheral Blood Hematopoietic Stem Cells Collection from Unrelated Donors]. [Effect of Endothelial Activation and Stress Index(EASIX) on Prognosis of Peripheral T-Cell Lymphoma Patient]. [Effect of JMJD3-IRF4 Signaling Pathway-Mediated Macrophage Polarization on the Malignant Biological Behavior of Multiple Myeloma Cells]. [Effect of Tumor Suppressor Gene Kmt2c Heterozygous Deletion on Hematopoietic System in Mice]. [Effects of ATG5 and ATG7 Knockout on Ferroptosis Sensitivity of RPMI-8226 Cells].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1